Key result
Third BNT-162b2 mRNA vaccine dose linked to myocarditis with unusual regional wall motion anomalies.
Why the study?
Despite the broad safety of mRNA vaccines, rare life-threatening side effects such as myocarditis have been reported.
Case Report (n=1)
COVID-19 mRNA vaccines can rarely cause myocarditis that may present with unusual regional wall motion anomalies on echocardiogram.
Alerts clinicians to monitor for myocarditis post-mRNA vaccination in young males; case report leaves open true incidence and risk factors.
The development of messenger ribonucleic acid (mRNA) vaccines has revolutionized the field of preventive medicine. These came into the spotlight during the COVID-19 pandemic. Despite the fact that vaccines are broadly safe, some rare, life-threatening side effects have been reported in the recent past, and myocarditis is one of them. We present a case of COVID-19 mRNA vaccine-induced myocarditis in a young male. Three days after receiving the third dose of the BNT-162b2 mRNA vaccine for COVID-19, he presented to the emergency department after experiencing palpitations. He was admitted to the hospital due to raised cardiac enzymes and a concerning echocardiogram. Magnetic resonance imaging the following day revealed myocarditis. There have been multiple cases of myocarditis reported in the literature owing to the COVID-19 mRNA vaccine. This case stands out because of the presence of regional wall motion anomalies in the echocardiogram, which is an unusual finding in patients with myocarditis. We recommend keeping a low threshold for investigating young patients presenting with cardiovascular symptoms who have received a recent COVID-19 mRNA vaccine.
No takes yet. Share an insight, caveat, or question.
Rehman et al. (2023) conducted a case report in COVID-19 vaccine-induced myocarditis (n=1). BNT-162b2 mRNA vaccine was evaluated on Myocarditis with regional wall motion anomalies. A young male developed myocarditis with unusual regional wall motion anomalies on echocardiogram three days after receiving a third dose of the BNT-162b2 mRNA COVID-19 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: